Liu Jingdian, Wu Sisi, Zhao Kai, Wang Junwen, Shu Kai, Lei Ting
Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Oncol. 2022 May 30;12:915273. doi: 10.3389/fonc.2022.915273. eCollection 2022.
Because of the low incidence and the constantly changing diagnostic and classification criteria, the clinical features, management, and prognostic factors of intracranial solitary fibrous tumor (ISFT) remain unclear and were thus analyzed in this study.
A total of 38 patients with ISFTs who were diagnosed in our institution were enrolled in this study. Patient data including age, gender, clinical presentation, histopathological features, immunohistochemistry staining, tumor location, tumor size, treatment methods, and prognosis were extracted and retrospectively analyzed.
The median age at diagnosis was 45.5 years (range 28-66 years) and the male-to-female ratio was 1:1.53 in our series. The 3-, 5-, and 10-year progression-free survival (PFS) rate was 82.2%, 62.8%, and 21.4%, respectively; and the 3-, 5-, and 10-year overall survival rate was 97.1%, 86.9%, and 64.2%, respectively. Patients with high WHO grade (grade 3) ISFTs experienced impaired PFS (p < 0.05) and OS (p < 0.01). Subtotal resection (STR) was associated with worse PFS and OS (p < 0.001, respectively). Postoperative radiotherapy (PORT) improved PFS, especially local control rate, in patients with WHO grade 3 ISFTs (P = 0.025) or STR (p = 0.027). Moreover, CD34-negative immunostaining and a high Ki-67 index (>10%) were associated with impaired PFS in ISFTs.
Our study provides evidence that high tumor grade, subtotal tumor resection, CD34 negative immunostaining, and high Ki-67 index (>10%) were independent predictors for the poor prognosis of ISFTs. PORT can improve local control rate, and should be recommended for patients with high-grade ISFTs or STR.
由于颅内孤立性纤维瘤(ISFT)发病率低且诊断和分类标准不断变化,其临床特征、治疗方法及预后因素仍不明确,因此本研究对其进行分析。
本研究纳入了在我院诊断为ISFT的38例患者。提取患者的年龄、性别、临床表现、组织病理学特征、免疫组化染色、肿瘤位置、肿瘤大小、治疗方法及预后等数据,并进行回顾性分析。
本系列研究中,诊断时的中位年龄为45.5岁(范围28 - 66岁),男女比例为1∶1.53。3年、5年和10年无进展生存率(PFS)分别为82.2%、62.8%和21.4%;3年、5年和10年总生存率分别为97.1%、86.9%和64.2%。世界卫生组织(WHO)高级别(3级)ISFT患者的PFS(p < 0.05)和总生存期(OS,p < 0.01)受损。次全切除(STR)与更差的PFS和OS相关(分别为p < 0.001)。术后放疗(PORT)改善了WHO 3级ISFT患者(P = 0.025)或接受STR患者(p = 0.027)的PFS,尤其是局部控制率。此外,CD34免疫染色阴性和高Ki-67指数(>10%)与ISFT患者的PFS受损相关。
我们的研究表明,高肿瘤级别、肿瘤次全切除、CD34免疫染色阴性和高Ki-67指数(>10%)是ISFT预后不良的独立预测因素。PORT可提高局部控制率,推荐用于高级别ISFT或接受STR的患者。